Mechanism of Action
Ferroportin Internalization
Hepcidin binds ferroportin (FPN/SLC40A1) extracellular domain, triggering tyrosine phosphorylation of FPN's intracellular C-terminal, ubiquitination, and clathrin-mediated endocytosis followed by lysosomal degradation. Loss of FPN from the cell surface prevents cellular iron export: duodenal enterocytes retain absorbed iron (reduced dietary uptake), and macrophages retain iron from senescent red blood cell recycling (iron sequestration). Net effect: reduced serum iron and transferrin saturation.
Regulation by BMP and Inflammation
Hepatic hepcidin expression is primarily controlled by the BMP/SMAD pathway: BMP6 (released by liver sinusoidal endothelial cells in response to high iron) binds BMPR2/ALK2/3 with coreceptor hemojuvelin, activating Smad1/5/8 and hepcidin transcription. Inflammation activates IL-6/STAT3, independently driving hepcidin expression regardless of iron stores, explaining iron-restricted anemia in chronic inflammatory disease. Erythropoietic demand (erythroferrone from erythroblasts) suppresses hepcidin to mobilize iron for RBC production.
Research Summary
Hereditary Hemochromatosis
Established MechanismMost hereditary hemochromatosis is caused by HFE mutations (C282Y) that impair hepcidin stimulation, resulting in uninhibited ferroportin and iron overabsorption. TMPRSS6, hemojuvelin, and hepcidin mutations also cause hemochromatosis. Hepcidin agonists (minihepcidins, TMPRSS6 siRNA, BMP6-SMAD pathway activators) are in Phase 1/2 trials to restore hepcidin signaling and prevent iron accumulation.
Anemia of Chronic Disease
Active Research (Antagonists)Anemia of inflammation (ACI) is the second most common anemia worldwide: IL-6-driven hepcidin excess sequesters iron in macrophages, causing iron-restricted erythropoiesis despite adequate iron stores. Anti-hepcidin antibodies (LY3232094), anti-IL-6R (tocilizumab reduces hepcidin), TMPRSS6 activators, and ferroportin stabilizers are being developed to overcome hepcidin-driven iron sequestration and treat ACI.
Beta-Thalassemia and Polycythemia Vera
Phase 1/2In beta-thalassemia, ineffective erythropoiesis suppresses hepcidin despite iron overload, worsening iron accumulation. Minihepcidins (SEG-011) and TMPRSS6 siRNA (SLN124) in Phase 1/2 trials restore hepcidin-like activity to reduce iron overload in beta-thalassemia. In polycythemia vera, reducing iron availability by increasing hepcidin activity may control erythrocytosis.
Calculate your Hepcidin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Iron overload model treatment | 0.1-10 mg/kg SC hepcidin or minihepcidins in thalassemia/hemochromatosis mouse models | 2-3x/week | Subcutaneous |
| ACI model (hepcidin blockade) | Anti-hepcidin antibody 3-30 mg/kg IV in inflammatory anemia models | Weekly | Intravenous |
Native hepcidin-25 has poor SC bioavailability; minihepcidins (engineered analogs) show improved stability and activity. Clinical trials use either native hepcidin/analogs (agonist) or antibody/siRNA approaches (antagonist).
Interactions
Safety Profile
Native hepcidin research doses: transient serum iron reduction; no significant toxicity at moderate doses in animals. Excessive hepcidin activity would cause iron-deficiency anemia and functional iron deficiency. Minihepcidins in Phase 1 show acceptable tolerability with primary pharmacological effect of iron reduction; no significant organ toxicity. Anti-hepcidin agents (antagonists) risk over-mobilizing iron stores, potentially causing oxidative stress; monitoring of serum ferritin and transferrin saturation required. Antimicrobial activity of native hepcidin-25 is weak at physiological concentrations.
References
- [1]Nemeth E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093.
- [2]Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-4433.